SPORTS randomized controlled trial results
SPORTS is the first investigator-sponsored, core-lab adjudicated, prospective, multi-centre, three-arm RCT comparing outcomes of DES (EluviaTM) vs. BMS (investigator choice) vs. DCB (SeQuent Please), 1:1:1, in TASC C/D lesions.1
SPORTS RTC 1-Year percentage diameter stenosis results
Eluvia demonstrated statistically superior performance over BMS, whilst DCB was only non-inferior to BMS when evaluated angiographically for percent diameter stenosis and late lumen loss at 12 months.

SPORTS RTC 1-Year freedom from CD-TLR results
Eluvia also demonstrated superior patient outcomes over BMS and DCB as evidenced by freedom from TLR through the 12-month follow-up period.

SPORTS randomized controlled trial details
- 1-year results
- Baseline characteristics
| Eluvia DES (n=74) | DCB (n=74) | BMS (n=76) | p-value |
Average Diameter Stenosis in Lesion | 25.3% | 53.7% | 60.0% | <0.0001 |
Average Late Lumen Loss | 0.4mm | 1.1mm | 2.0mm | <0.0001 |
K-M Freedom from CD-TLR | 94.5% | 80.7% | 77.4% | 0.015 |